

BOMI LLC Announces Issuance Of U.S.A. Patent for the Anti-Cannabidiol Antibody and Uses Thereof

Patented Cannabidiol Antibody selectively measures the "Bioactive" quality of Cannabidiol (CBD)

LAS VEGAS, NEVADA, USA, January 23, 2024 /EINPresswire.com/ -- BOMI LLC, a Nevada LLC, announces the issuance of USPTO Patent# 11,860,174 for an anti-cannabidiol antibody which highly selectively binds cannabidiol (CBD), and not other cannabinoids.

Cannabidiol (CBD) is one of the hottest supplements in the market. The industry standard method of measuring CBD is by a Certificate Of Analysis (COA) which measures the "mass" of CBD (normally mg/ml.) COA does not measure the quality of the CBD. This has caused the market to be flooded with CBD of poor quality.

COA also does not differentiate between natural Cannabidiol and synthetic Cannabidiol. [Scientific studies](#) have shown that synthetic CBD elevates liver enzymes and is harmful to human health. Natural CBD does not elevate liver enzymes. The current invention is a critical tool to separate natural CBD from harmful synthetic CBD.


"We need more inventions such as this. Natural Cannabidiol is one of the best antagonists for cytokines ([WHO Report on Cannabidiol](#)). It is a potent reducer of inflammation- only if it works. The CBD has to be natural and highly bioactive in quality" says Dr. Avi Cohen, a Director at the World Health Organization Traditional Complimentary and Integrative Medicine (TCIM), Geneva, Switzerland. "This Anti-Cannabidiol antibody is currently the only way to ensure that the CBD you are using is effective in the human body."


 US011860174B2

(12) United States Patent Joseph (54) ANTI-CANNABIDIOL ANTIBODY AND USES THEREOF (71) Applicant: BOMI, LLC, Reno, NV (US) (72) Inventor: Bomi Joseph, Reno, NV (US) (73) Assignee: BOMI LLC, Sparks, NV (US) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 495 days. (21) Appl. No.: 16/772,167 (22) PCT Filed: Dec. 14, 2018 (86) PCT No.: PCT/US2018/065658 § 371 (c)(1), (2) Date: Jun. 12, 2020 (87) PCT Pub. No.: WO2019/118831 PCT Pub. Date: Jun. 20, 2019 (65) Prior Publication Data US 2021/0072265 A1 Mar. 11, 2021 Related U.S. Application Data (60) Provisional application No. 62/599,501, filed on Dec. 15, 2017. (51) Int. Cl. G01N 33/94 (2006.01) C07K 16/16 (2006.01) (52) U.S. Cl. G01N 33/948 (2013.01); C07K 16/16 (2013.01); C07K 2317/622 (2013.01)	(10) Patent No.: US 11,860,174 B2 (45) Date of Patent: Jan. 2, 2024 (58) Field of Classification Search CPC .. C07K 16/16; C07K 16/44; C07K 2317/622; G01N 33/948 See application file for complete search history. (56) References Cited U.S. PATENT DOCUMENTS 2006/0019260 A1 1/2006 Lerner et al. 2009/0297449 A1 12/2009 Devy 2011/0086364 A1 4/2011 Takkinen et al. FOREIGN PATENT DOCUMENTS CN 101580544 B 10/2012 OTHER PUBLICATIONS Search Opinion dated Nov. 29, 2021 for EP 3724657, Application No. 18887995.1, filed Dec. 14, 2018.* International Search Report and Written Opinion for PCT/US2018/065658, dated May 6, 2019. UniProtKB Accession No. P01649 for KV5AG-Mouse (1986). * cited by examiner Primary Examiner — Galina M. Yakovleva (74) Attorney, Agent, or Firm — Banner & Witcoff, Ltd. (57) ABSTRACT This invention relates to anti-cannabidiol antibodies and methods of using these antibodies for the detection and quantification of bioactive cannabidiol. 17 Claims, 5 Drawing Sheets Specification includes a Sequence Listing.
--	---

Anti-Cannabidiol Antibody Patent# 11,860,174
First Page

Dr. Surinder Kumar headed the Research and Development of several Fortune 100 Companies, including Unilever, Quaker Oats Company, Frito Lay, PepsiCo, Warner Lambert, Mead Johnson and the Wm. Wrigley Jr Company. He states, "This is what we have been waiting for. There is a lot of interest in CBD, in the food and beverage market. We have always measured the mass of the CBD but we have never had a measure of it's quality. We need to know that the CBD is natural and of a high quality before we can add to a product that is ingested."



BOMI LLC has been licensing the patented anti-Cannabidiol antibody to [BioactiveCBD](http://BioactiveCBD.com) Labs worldwide. For more information on BioactiveCBD please visit www.BioactiveCBD.org or call +1-888-337-4986.

“


We need more inventions such as this... The CBD has to be natural and highly bioactive in quality. This is currently the only way to ensure that the CBD you are using is effective in the human body.”

*Dr. Avi Cohen, Director, WHO
TCIM*

BOMI LLC

Is a Limited Liability Corporation, based out of Las Vegas, Nevada. BOMI LLC is an intellectual property company that holds numerous papers, trademarks and patents revolving around “health.” It is dedicated to helping people measure and improve their health naturally – without drugs.

Ashwin Chaudary
BOMI LLC
+1 888-337-4986
[email us here](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/683065353>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.